Rodica Maricela Anghel

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 503 citations · Full text

Medicine, Oncology, Radiation Oncology +13

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

Alba A. Brandes, Miguel Gil‐Gil, Frank Saran et al. · The Oncologist · 2018 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · International Journal of Radiation Oncology*Biology*Physics · 2022 · 44 citations · Full text

Medicine, Oncology, Radiation Oncology +15

Outcome of urinary bladder cancer after combined therapies.

Rodica Maricela Anghel, Laurenţia Galeş, Oana Trifănescu · PubMed · 2017 · 31 citations · Full text

Medicine, Oncology, Surgery +16

A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer

Antonio Llombart‐Cussac, Miguel Martín, Nadia Harbeck et al. · Clinical Cancer Research · 2007 · 28 citations

Medicine, Oncology, Pharmacology +15